Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults;Cambios en los Medicamentos Hipocolesterolemiantes Utilizados a lo Largo de una Década en Pacientes Mayores Residentes en la Comunidad

Annals of Pharmacotherapy

Volumn 47, Issue 7-8, 2013, Pages 984-992

  Lo Ciganic, Wei Hsuan ^a   Boudreau, Robert M ^a   Gray, Shelly L ^b   Zgibor, Janice C ^a   Donohue, Julie M ^a   Perera, Subashan ^c   Newman, Anne B ^a   Simonsick, Eleanor M ^d   Bauer, Douglas C ^e   Satterfield, Suzanne ^f   Hanlon, Joseph T ^c,g  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g Peter M Winter Institute for Simulation Education and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PROBUCOL;

AGED; ARTICLE; COHORT ANALYSIS; DRUG USE; FEMALE; FOLLOW UP; HEALTH BEHAVIOR; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENESCENCE; TIME SERIES ANALYSIS;

AGE FACTORS; AGED; CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RESIDENCE CHARACTERISTICS; TIME FACTORS;

EID: 84880078059     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1S050     Document Type: Article

References (59)

1. Schwartz JB, Zipes DP. Cardiovascular disease in the elderly. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald's heart disease-a textbook of cardiovascular medicine. 9th ed. Philadelphia, PA: Saunders, an imprint of Elsevier, 2011:1727-57.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012;125:e2-e220. doi: 10.1161/CIR.0b013e31823ac046
3. National Center for Health Statistics. Health, United States, 2010: with special features on death and dying. Hyattsville, MD, 2011.
4. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-98. doi: 10.1056/NEJMsa053935
5. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 1988;148:36-69.
6. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
8. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. doi: 10.1161/01.CIR.0000133317.49796.0E
9. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-8.
10. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681-9.
11. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001;134:931-40.
12. MRC/BHF Heart Protection Study of cholesterol lowering with simva-statin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. doi: 10.1016/S0140-6736(02)09327-3
13. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008;51:37-45. doi: 10.1016/j.jacc.2007.06.063
14. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
15. Li M, Ong KL, Tse HF, Cheung BM. Utilization of lipid lowering medications among adults in the United States 1999-2006. Atherosclerosis 2010;208:456-60. doi: 10.1016/j.atherosclerosis.2009.08.001
16. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-65.
17. Kamari Y, Bitzur R, Cohen H, Shaish A, Harats D. Should all diabetic patients be treated with a statin? Diabetes Care 2009;32(suppl 2):S378-83.
18. Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing 2010;39:674-80. doi: 10.1093/ageing/afq129
19. Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med 2005;3:6. doi: 10.1186/1741-7015-3-6
20. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61. doi: 10.1056/NEJMoa0706201
21. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27:299-309.
22. Simonsick EM, Newman AB, Nevitt MC, et al. Measuring higher level physical function in well-functioning older adults: expanding familiar approaches in the Health ABC study. J Gerontol A Biol Sci Med Sci 2001; 56:M644-9.
23. Newman AB, Haggerty CL, Kritchevsky SB, Nevitt MC, Simonsick EM. Walking performance and cardiovascular response: associations with age and morbidity-the Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med Sci 2003;58:715-20.
24. Holvoet P, Harris TB, Tracy RP, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition Study. Arterioscler Thromb Vasc Biol 2003;23:1444-8. doi: 10.1161/01.ATV.0000080379.05071.22
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
26. Newman AB, Simonsick EM, Naydeck BL, et al. Association of longdistance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA 2006;295:2018-26. doi: 10.1001/jama.295.17.2018
27. de Rekeneire N, Rooks RN, Simonsick EM, et al. Racial differences in glycemic control in a well-functioning older diabetic population: findings from the Health, Aging and Body Composition Study. Diabetes Care 2003;26:1986-92.
28. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994;10:405-11.
29. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol 1992;45:683-92.
30. Setoguc S, Glynn RJ, Avorn J, Levin R, Winkelmayer WC. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons ≥65 years of age. Am J Cardiol 2007;100: 1061-7. doi: 10.1016/j.amjcard.2007.04.052
31. Lemaitre RN, Furberg CD, Newman AB, et al. Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. Arch Intern Med 1998;158:1761-8.
32. Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of fibrates in the United States and Canada. JAMA 2011;305:1217-24. doi: 10.1001/jama.2011.353
33. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and lowdensity lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008;42:1208-15. doi: 10.1345/aph.1L181
34. National Heart, Lung, and Blood Institute (NHLBI) clinical guidelines on identification, evaluation and treatment of overweight and obesity in adults, 1998. www.nhlbi.nih.gov/guidelines/obesity/ob_home.htm (accessed 2013 Jun 10).
35. Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 2003;38:1103-20.
36. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314-8.
37. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psych Measur 1977;1:385-401. doi: 10.1177/014662167700100306
38. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003;61:76-80.
39. Diggle PJ, Heagerty P, Liang K-Y, Zeger SL, eds. Analysis of longitudinal data. 2nd ed. New York: Oxford University Press Inc., 2002.
40. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA 2008;299:1922-8. doi: 10.1001/jama.299.16.1922
41. Rubin DB, ed. Multiple imputation for nonresponse in surveys. New York: John Wiley and Sons, 1987.
42. Grol R, Zwaard A, Mokkink H, Dalhuijsen J, Casparie A. Dissemination of guidelines: which sources do physicians use in order to be informed? Int J Qual Health Care 1998;10:135-40.
43. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499-510. doi: 10.1161/01.CIR.0000154568.43333.82
44. Robinson JG, Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol 2010;4:483-90. doi: 10.1016/j.jacl.2010.10.002
45. Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 2000;108:496-9.
46. Riahi S, Fonager K, Toft E, et al. Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark. Br J Clin Pharmacol 2001;52:307-11.
47. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004;291: 1864-70. doi: 10.1001/jama.291.15.1864
48. Aronow WS. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol >125 mg/dL. Am J Cardiol 1998;82:668-9, A6, A8.
49. Massing MW, Sueta CA, Chowdhury M, Biggs DP, Simpson RJ Jr. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol 2001;87:646-9, A10.
50. Thomas JE, Tershakovec AM, Jones-Burton C, Sayeed RA, Foody JM. Lipid lowering for secondary prevention of cardiovascular disease in older adults. Drugs Aging 2010;27:959-72. doi: 10.2165/11539550-000000000-00000
51. Robinson JG. Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges. Drugs Aging 2009;26:917-31. doi: 10.2165/11318270-000000000-00000
52. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
53. Field MJ, Lohr KN, eds. Guidelines for clinical practice: from development to use. Washington, DC: National Academy Press, 1992.
54. Green LW. Making research relevant: if it is an evidence-based practice, where's the practice-based evidence? Fam Pract 2008;25(suppl 1):i20-4. doi: 10.1093/fampra/cmn055
55. Cournot M, Cambou JP, Quentzel S, Danchin N. Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: results from the ELIAGE and ELICOEUR surveys. Int J Cardiol 2006;111:12-8. doi: 10.1016/j.ijcard.2005.06.039
56. Morley JE. The cholesterol conundrum. J Am Geriatr Soc 2011;59:1955-6. doi: 10.1111/j.1532-5415.2011.03594.x
57. Tinetti ME, McAvay GJ, Fried TR, et al. Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes. J Am Geriatr Soc 2008;56:1409-16. doi: 10.1111/j.1532-5415.2008.01815.x
58. Raffel OC, White HD. Drug insight: statin use in the elderly. Nat Clin Pract Cardiovasc Med 2006;3:318-28.
59. Jacobson TA. Overcoming 'ageism' bias in the treatment of hypercholesterolaemia: a review of safety issues with statins in the elderly. Drug Saf 2006;29:421-48.